Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 501–600 of 1,060

A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
Laaksonen, R., Katajamaa, M., Päivä, H., Sysi‐Aho, M., Saarinen, L., Junni, P., Lütjohann, D., Smet, J., Coster, R. V., Seppänen‐Laakso, T., et al. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000097 · Cited by 223
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins
Shah, P. K., Kaul, S., Nilsson, J. Å., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4401.098467 · Cited by 223
An application of propensity score matching using claims data
Seeger, J. D., Williams, P. L., & Walker, A. M. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1062 · Cited by 218
Simvastatin Preserves the Structure of Coronary Adventitial Vasa Vasorum in Experimental Hypercholesterolemia Independent of Lipid Lowering
Wilson, S. H., Herrmann, J., Lerman, L. O., Holmes, D. R., Claudio Napoli, A., Ritman, E. L., & Lerman, A. (2002) · Circulation · doi:10.1161/hc0402.104119 · Cited by 221
Association of low serum total cholesterol with major depression and suicide
Partonen, T., Haukka, J. K., Virtamo, J. R. K., Taylor, P. R., & Lönnqvist, J. K. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.175.3.259 · Cited by 221
Reductase Inhibitor Monotherapy and Stroke Prevention
Crouse, J. R. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440330039004 · Cited by 221
Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia.
Kaufmann, P. A., Gnecchi-Ruscone, T., Schäfers, K. P., Lüscher, T. F., & Camici, P. G. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00697-5 · Cited by 217
Dyslipidemia and the Risk of Developing Hypertension in a Working‐Age Male Population
Otsuka, T., Takada, H., Nishiyama, Y., Kodani, E., Saiki, Y., Kato, K., & Kawada, T. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003053 · Cited by 228
Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients
Christians, U., Jacobsen, W., & Floren, L. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00016-3 · Cited by 222
Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol
Sukhova, G. K., Williams, J. K., & Libby, P. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000030360.72503.56 · Cited by 220
Effect of Cholesterol Reduction on Myocardial Ischemia in Patients With Coronary Disease
Andrews, T. C., Raby, K. E., Barry, J., Naimi, C., Allred, E. N., Ganz, P., & Selwyn, A. P. (1997) · Circulation · doi:10.1161/01.cir.95.2.324 · Cited by 220
Statins and Liver Toxicity: A Meta‐Analysis
de Denus, S., Spinler, S. A., Miller, K., & Peterson, A. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.6.584.34738 · Cited by 218
Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function
van Heek, M., Farley, C., Compton, D. S., Hoos, L. M., & Davis, H. R. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704260 · Cited by 217
Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women
Boekholdt, S. M., Kuivenhoven, J. A., Wareham, N. J., Peters, R. J. G., Jukema, J. W., Luben, R., Bingham, S. A., Day, N., Kastelein, J. J. P., & Khaw, K. (2004) · Circulation · doi:10.1161/01.cir.0000141730.65972.95 · Cited by 217
Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in ApoE Knockout Mice
Davis, H. R., Compton, D. S., Hoos, L., & Tetzloff, G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1201.100260 · Cited by 182
Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia
Marks, D., Wonderling, D. E., Thorogood, M., Lambert, H., Humphries, S. E., & Neil, H. A. W. (2002) · BMJ · doi:10.1136/bmj.324.7349.1303 · Cited by 221
Clinical Outcomes in Statin Treatment Trials
Ross, S. D., Allen, I. E., Connelly, J. E., Korenblat, B. M., Smith, M. E., Bishop, D. J., & Luo, D. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.15.1793 · Cited by 219
Statin myopathy: A common dilemma not reflected in clinical trials
Fernandez, G., Spatz, E. S., Jablecki, C. K., & Phillips, P. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10073 · Cited by 217
Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization
Libby, P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01339-4 · Cited by 218
Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome
Charchar, F. J., Bloomer, L. D. S., Barnes, T. A., Cowley, M. J., Nelson, C. P., Wang, Y., Denniff, M. J., Dębiec, R., Christofidou, P., Nankervis, S. A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61453-0 · Cited by 216
Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men
Haq, I. U., Ramsay, L. E., Yeo, W. W., Jackson, P., & Wallis, E. J. (1999) · Heart · doi:10.1136/hrt.81.1.40 · Cited by 214
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency
Tonelli, M. A., Bohm, C. J., Pandeya, S., Gill, J., Levin, A., & KIBERD, B. A. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.22070 · Cited by 215
New Tools for Coronary Risk Assessment
Pearson, T. A. (2002) · Circulation · doi:10.1161/hc0702.103727 · Cited by 216
Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions
Bucher, H. C., Griffith, L. E., & Guyatt, G. H. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.2.187 · Cited by 211
The Munster Heart Study (PROCAM)
Cullen, P., Schulte, H., & Assmann, G. (1997) · Circulation · doi:10.1161/01.cir.96.7.2128 · Cited by 212
Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types
Nègre‐Aminou, P., van Vliet, A. K., van Erck, M., van Thiel, G. C. F., van Leeuwen, R. E. W., & Cohen, L. (1997) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(96)00184-1 · Cited by 212
Effect of Rosuvastatin on Coronary Atheroma in Stable Coronary Artery Disease Multicenter Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS)
Takayama, T., Hiro, T., Yamagishi, M., Daida, H., Hirayama, A., Saito, S., Yamaguchi, T., Matsuzaki, M., & The COSMOS Investigators (2009) · Circulation Journal · doi:10.1253/circj.cj-09-0358 · Cited by 211
‘Mendelian randomization’: an approach for exploring causal relations in epidemiology
Gupta, V., Walia, G. K., & SACHDEVA, M. P. (2017) · Public Health · doi:10.1016/j.puhe.2016.12.033 · Cited by 216
Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle
Evans, M., & Rees, A. (2002) · Drug Safety · doi:10.2165/00002018-200225090-00004 · Cited by 211
Statins Are Associated With a Reduced Incidence of Perioperative Mortality After Coronary Artery Bypass Graft Surgery
Pan, W., Pintar, T., Anton, J. M., Lee, V., Vaughn, W. K., & Collard, C. D. (2004) · Circulation · doi:10.1161/01.cir.0000138316.24048.08 · Cited by 211
Outcomes in 45 Patients With Statin-Associated Myopathy
Hansen, K. E., Hildebrand, J. P., Ferguson, E. E., & Stein, J. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.22.2671 · Cited by 280
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney, J. M. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.7.697 · Cited by 217
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
Howard, W. J. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79115-7 · Cited by 209
Mendelian Randomization
Thanassoulis, G., & O’Donnell, C. J. (2009) · JAMA · doi:10.1001/jama.2009.812 · Cited by 209
How do we improve patient compliance and adherence to long-term statin therapy?
Maningat, P., Gordon, B. R., & Breslow, J. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0291-7 · Cited by 208
Phytosterols and vascular disease
Patel, M. D., & Thompson, P. D. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.026 · Cited by 208
Meta-Analysis of Randomized Trials for Medical Prevention of Calcium Oxalate Nephrolithiasis
Pearle, M. S., Roehrborn, C. G., & Pak, C. Y. C. (1999) · Journal of Endourology · doi:10.1089/end.1999.13.679 · Cited by 208
Preservation of Endogenous Antioxidant Activity and Inhibition of Lipid Peroxidation as Common Mechanisms of Antiatherosclerotic Effects of Vitamin E, Lovastatin and Amlodipine
Chen, L., Haught, W. H., Yang, B., Saldeen, T. G. P., Parathasarathy, S., & Mehta, J. L. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00158-7 · Cited by 208
Blood Rheology, Cardiovascular Risk Factors, and Cardiovascular Disease: The West of Scotland Coronary Prevention Study
Rumley, A., Norrie, J. D., Ford, I., Shepherd, J., Cobbe, S. M., Macfarlane, P. W., Packard, C. J., Lowe, G. D. O., & The West of Scotland Coronary Prevention Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614066 · Cited by 208
Survival in treated hypertension: follow up study after two decades
Andersson, O., Almgren, T., Persson, B., Samuelsson, O. G., Hedner, T., & Wilhelmsen, L. (1998) · BMJ · doi:10.1136/bmj.317.7152.167 · Cited by 208
Use of Statins and the Subsequent Development of Deep Vein Thrombosis
Ray, J. G., Mamdani, M., Tsuyuki, R. T., Anderson, D. R., Yeo, E. L., & Laupacis, A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1405 · Cited by 206
Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia
Ferro, D., Parrotto, S., Basili, S., Alessandri, C., & Violi, F. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00771-3 · Cited by 209
Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions
Chan, A. W., Bhatt, D. L., Chew, D. P., Reginelli, J. P., Schneider, J. P., Topol, E. J., & Ellis, S. G. (2003) · Circulation · doi:10.1161/01.cir.0000060541.18923.e9 · Cited by 207
Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor
OLSSON, A. G., McTaggart, F., & Raza, A. (2002) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2002.tb00099.x · Cited by 204
Simvastatin Exerts Both Anti-inflammatory and Cardioprotective Effects in Apolipoprotein E–Deficient Mice
Scalia, R. G., Gooszen, M. E., Jones, S. P., Hoffmeyer, M. R., Rimmer, D. M., Trocha, S. D., Huang, P. L., Smith, M. B., Lefer, A. M., & Lefer, D. J. (2001) · Circulation · doi:10.1161/01.cir.103.21.2598 · Cited by 204
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.
Knapp, H., Schrott, H., Ma, P., Knopp, R. H., Chin, B., Gaziano, J., Donovan, J. M., Burke, S., & Davidson, M. H. (2001) · American Journal of Medicine · doi:10.1016/s0002-9343(01)00638-6 · Cited by 201
The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin
Jaime, J., Klittich, W. S., McGuire, A. J., Ford, I., Norrie, J. D., Pettitt, D., McMurray, J. J. V., & Shepherd, J. (1997) · BMJ · doi:10.1136/bmj.315.7122.1577 · Cited by 203
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230
Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions
Khanal, S., Attallah, N. M., Smith, D. E., Kline-Rogers, E. M., Share, D. A., O’Donnell, M. J., & Moscucci, M. M. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.03.031 · Cited by 198
Simvastatin attenuates cisplatin-induced kidney and liver damage in rats
İşeri, S. Ö., Ercan, F., Gedik, N., Yüksel, M., & Ali̇can, İ. (2006) · Toxicology · doi:10.1016/j.tox.2006.11.073 · Cited by 201
Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy
Steinberg, D. H. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600009-jlr200 · Cited by 205
A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acid
Stalker, T. J., Lefer, A. M., & Scalia, R. G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704070 · Cited by 202
Insulin Resistance and Atherosclerosis
Razani, B., Chakravarthy, M. V., & Semenkovich, C. F. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.05.001 · Cited by 201
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation
Blanco‐Colio, L. M., Villa, A., Ortego, M., Hernández-Presa, M. Á., Pascual, A., Plaza, J. J. G., & Egido, J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00613-x · Cited by 201
Statins and Stroke
Endres, M. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600116 · Cited by 205
Beyond the Laboratory
Halcox, J., & Deanfield, J. E. (2004) · Circulation · doi:10.1161/01.cir.0000129500.29229.92 · Cited by 200
Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL
Yvan‐Charvet, L., Matsuura, F., Wang, N., Bamberger, M. J., Nguyen, T. T., Rinninger, F., Jiang, X., Shear, C. L., & Tall, A. R. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.106.138347 · Cited by 200
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
von Haehling, S., & Anker, S. D. (2004) · Heart · doi:10.1136/hrt.2004.042515 · Cited by 201
Efficacy of Ranolazine in Patients With Chronic Angina
Wilson, S. R., Scirica, B. M., Braunwald, E., Murphy, S. A., Karwatowska-Prokopczuk, E., Buros, J. L., Chaitman, B. R., & Morrow, D. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.037 · Cited by 198
A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin
White, C. M. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127000204200902 · Cited by 221
Effects of Diet and Simvastatin on Serum Lipids, Insulin, and Antioxidants in Hypercholesterolemic Men
Jula, A., Marniemi, J., Huupponen, R., Virtanen, A., Rastas, M., & Rönnemaa, T. (2002) · JAMA · doi:10.1001/jama.287.5.598 · Cited by 197
Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy
Ballantyne, C. M., Herd, J. A., Ferlic, L. L., Dunn, J. K., Farmer, J. A., Jones, P. H., Schein, J. R., & Gotto, A. M. (1999) · Circulation · doi:10.1161/01.cir.99.6.736 · Cited by 198
Modified natural nanoparticles as contrast agents for medical imaging
Cormode, D. P., Jarzyna, P. A., Mulder, W. J. M., & Fayad, Z. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.005 · Cited by 200
Coronary Atherosclerotic Plaque Regression
Dawson, L. P., Lum, M., Nerlekar, N., Nicholls, S. J., & Layland, J. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.10.035 · Cited by 209
Statin-Induced Cholesterol Lowering and Plaque Regression After 6 Months of Magnetic Resonance Imaging–Monitored Therapy
Lima, J. A. C., Desai, M. Y., Steen, H., Warren, W. P., Gautam, S., & Lai, S. (2004) · Circulation · doi:10.1161/01.cir.0000145170.22652.51 · Cited by 198
Statin Trials and Goals of Cholesterol-Lowering Therapy
Grundy, S. M. (1998) · Circulation · doi:10.1161/01.cir.97.15.1436 · Cited by 197
Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients
KOBASHIGAWA, J. A., Moriguchi, J. D., Laks, H., Wener, L., Hage, A., Hamilton, M. A., Cogert, G., Marquez, A., Vassilakis, M. E., Patel, J. K., et al. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2005.02.009 · Cited by 193
Validation of the Archimedes Diabetes Model
Eddy, D. M., & Schlessinger, L. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3102 · Cited by 192
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease
Tonelli, M. A., Isles, C., Craven, T. E., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C. D., Cobbe, S. M., Simes, J. R., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.517565 · Cited by 190
Clinically relevant differences between the statins: implications for therapeutic selection
Chong, P. H., Seeger, J. D., & Franklin, C. M. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00870-1 · Cited by 195
Are lipid-lowering drugs also antiarrhythmic drugs?
Mitchell, L. B., Powell, J. L., Gillis, A. M., Kehl, V., & Hallstrom, A. P. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00498-4 · Cited by 196
Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12000 men and women from The Copenhagen City Heart Study
Schnohr, P. (2002) · European Heart Journal · doi:10.1053/euhj.2001.2842 · Cited by 195
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000133317.49796.0e · Cited by 196
Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
Vijan, S. S., & Hayward, R. A. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-8-200404200-00013 · Cited by 192
The Impact of the Aging Population on Coronary Heart Disease in the United States
Odden, M. C., Coxson, P. G., Moran, A., Lightwood, J. M., Goldman, L., & Bibbins-Domingo, K. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.04.010 · Cited by 235
Proportion and Risk Indicators of Nonadherence to Statin Therapy: A Meta-analysis
Lemstra, M., Blackburn, D. F., Crawley, A., & Fung, R. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.05.007 · Cited by 201
Cerivastatin Improves Survival of Mice with Lipopolysaccharide-Induced Sepsis
Ando, H., Takamura, T., Ota, T., Nagai, Y., & Kobayashi, K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39169-4 · Cited by 192
Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 197
Current and future treatment of hyperlipidemia: the role of statins.
Farnier, M., & Davignon, J. (1998) · American Journal of Cardiology · doi:10.1016/s0002-9149(98)00423-8 · Cited by 196
Do statins cause cancer? A meta-analysis of large randomized clinical trials
Bjerre, L. M., & LeLorier, J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00705-7 · Cited by 194
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Cholesterol and Violence: Is There a Connection?
Golomb, B. A. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-6-199803150-00009 · Cited by 193
Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions
Psaty, B. M., Furberg, C. D., Ray, W. A., & Weiss, N. S. (2004) · JAMA · doi:10.1001/jama.292.21.2622 · Cited by 191
Diagnosis, prevention, and intervention for the metabolic syndrome
SCOTT, C. L. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00507-1 · Cited by 193
Association of Mutations in the Apolipoprotein B Gene with Hypercholesterolemia and the Risk of Ischemic Heart Disease
Tybjærg‐Hansen, A., Steffensen, R., Meinertz, H., Schnohr, P., & Nordestgaard, B. G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805283382203 · Cited by 191
Physician Noncompliance With the 1993 National Cholesterol Education Program (NCEP-ATPII) Guidelines
Frolkis, J. P., Zyzanski, S. J., Schwartz, J. M., & Suhan, P. S. (1998) · Circulation · doi:10.1161/01.cir.98.9.851 · Cited by 191
Endothelial Function and Oxidative Stress
Ogita, H., & Liao, J. K. (2004) · Endothelium · doi:10.1080/10623320490482664 · Cited by 191
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181
Self-citation
Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia
Westin, G. G., Armstrong, E. J., Bang, H., Yeo, K.-K., Anderson, D., Dawson, D. L., Pevec, W. C., Amsterdam, E. A., & Laird, J. R. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.073 · Cited by 189
Hepatotoxicity of statins and other lipid‐lowering agents
Björnsson, E. S. (2017) · Liver International · doi:10.1111/liv.13308 · Cited by 173
Effect of statins on toll-like receptors: a new insight to pleiotropic effects
Bahrami, A., Parsamanesh, N., Atkin, S. L., Banach, M., & Sahebkar, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.014 · Cited by 192
Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL
Cheung, M. C., Zhao, X.-Q., Chait, A., Albers, J. J., & Brown, B. G. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0801.095151 · Cited by 192
Echo-Lucency of Computerized Ultrasound Images of Carotid Atherosclerotic Plaques Are Associated With Increased Levels of Triglyceride-Rich Lipoproteins as Well as Increased Plaque Lipid Content
Grønholdt, M.-L. M., Nordestgaard, B. G., Wiebe, B. M., Wilhjelm, J. E., & Sillesen, H. H. (1998) · Circulation · doi:10.1161/01.cir.97.1.34 · Cited by 188
Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women
Darling, G. M., Johns, J., McCloud, P., & Davis, S. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370903 · Cited by 189
Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation
Abela, G. S. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.03.003 · Cited by 192
Vulnerable Plaque: Pathobiology and Clinical Implications
Kullo, I., Edwards, W. D., & Schwartz, R. S. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00010 · Cited by 188
Impact of Plasma Oxidized Low-Density Lipoprotein Removal on Atherosclerosis
Ishigaki, Y., Katagiri, H., Gao, J., Yamada, T., Imai, J., Uno, K., Hasegawa, Y., Kaneko, K., Ogihara, T., Ishihara, H., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.745174 · Cited by 187
Statins and Intracerebral Hemorrhage
Hackam, D. G., Woodward, M., Newby, L. K., Bhatt, D. L., Shao, M., Smith, E. E., Donner, A., Mamdani, M., Douketis, J. D., Arima, H., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.055269 · Cited by 189
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
Pletcher, M. J., Lazar, L., Bibbins-Domingo, K. B., Moran, A., Rodondi, N., Coxson, P. G., Lightwood, J., Williams, L., & Goldman, L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-4-200902170-00005 · Cited by 187

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks